Compass Therapeutics: Tovecimig meets primary endpoint in BTC trial; Q1 net loss $16.6M

Compass Therapeutics, Inc.

Tovecimig + paclitaxel achieved 17.1% ORR (incl. 1 complete response) vs 5.3% for paclitaxel alone (p=0.031) in Phase 2/3 BTC study.
Secondary endpoints PFS, OS, DoR analyses expected Q4 2025; pre-specified event count not yet met.
Q1 2025 net loss $16.6M ($0.12/sh), R&D $13.1M (+37% YoY), cash $113M providing runway into 2027.
CTX-10726 (PD-1 x VEGF-A) pre-IND meeting completed; IND filing expected Q4 2025.
CTX-8371 Phase 1 dose-escalation advanced to 4th cohort with no DLTs; preliminary data H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.